Evidence map›Paper›PMID 42643793›Full record

ArticleJournal of Cancer2026

PKM2 is the Metabolic Checkpoint for Stemness Features in Head and Neck Cancer.

Wan-Hsuan Sun, Ta-Jung Peng, Hsueh-Jou Fang, Chia-Ling Chang, Yu-Wen Tang, Kuang-Hui Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wan-Hsuan SunDivision of Head & Neck Surgery, Department of Otolaryngology, Tri-Service General Hospital and National Defense Medical University, Taipei 114, Taiwan.
Ta-Jung PengDepartment of Biotechnology and Laboratory Science in Medicine, Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Hsueh-Jou FangDepartment of Biotechnology and Laboratory Science in Medicine, Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Chia-Ling ChangDepartment of Biotechnology and Laboratory Science in Medicine, Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Yu-Wen TangDivision of Oral & Maxillofacial Surgery, Department of Stomatology, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Kuang-Hui SunDepartment of Biotechnology and Laboratory Science in Medicine, Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to their self-renewal, differentiation capabilities, and increased chemoresistance, cancer stem cells (CSCs) are associated with poor prognosis and an elevated chance of relapse and metastasis. CSCs survive under therapy-imposed pressure and aggravate tumor malignancy through metabolic reprogramming, leading to treatment failure. The RNA level of pyruvate kinase isoenzyme M2 (

Indexed as

cancer metabolismcancer stemnesshead and neck cancer.PKM2Wnt/β-catenin

Identifiers

PMID42643793
PMCPMC13505365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.